Sarepta Jumps after FDA Nod  for Gene Therapy
Market News

Sarepta Jumps after FDA Nod for Gene Therapy

Shares of the company for precision genetic medicine for rare diseases, Sarepta Therapeutics (NASDAQ: SRPT) jumped in pre-market trading at the time of publishing on Monday after the company’s SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with Duchenne muscular dystrophy received a nod from the U.S. FDA for accelerated approval.

The FDA’s Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in favor of accelerated approval for the drug and the vote “while not binding, will be considered by the FDA when making its decision regarding the potential accelerated approval of SRP-9001. The Biologics License Application (BLA) for SRP-9001 is currently under priority review by the FDA with a regulatory action date of May 29, 2023.”

Analysts are bullish about SRPT stock with a Strong Buy consensus rating based on 19 Buys and three Holds.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles